| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:galacto-Dapagliflozin
CAS:1408245-02-2
Purity:95% Package:1G;10G;100G Remarks:Galacto-Dapagliflozin potently inhibits human SGLT2 (Ki = 2 nM) which is 1,000-fold less potent at human SGLT1 (Ki = 25,000).
|
| Company Name: |
Hubei Xinyang Medical Technology Co., Ltd
|
| Tel: |
15347293736 15347293736 |
| Email: |
2853117764@qq.com |
| Products Intro: |
Product Name:Dapagliflozin Impurity 43
CAS:1408245-02-2
Purity:99% HPLC Package:10mg;25mg;50mg;100mg;200mg;500mg
|
| Company Name: |
MedBioPharmaceutical Technology Inc
|
| Tel: |
021-69568360 18916172912 |
| Email: |
order@med-bio.cn |
| Products Intro: |
Product Name:galacto-Dapagliflozin
CAS:1408245-02-2
Purity:98% Package:10mg; 50mg; 1mg; 5mg Remarks:Medbio
|
| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:galacto-Dapagliflozin
CAS:1408245-02-2
Purity:95% Package:1mg;5mg;10mg
|
| Company Name: |
ApexBio Technology
|
| Tel: |
+ 1-832-696-8203 |
| Email: |
sales@apexbt.com |
| Products Intro: |
Product Name:galacto-Dapagliflozin
CAS:1408245-02-2
|
|
| | galacto-Dapagliflozin Basic information |
| Product Name: | galacto-Dapagliflozin | | Synonyms: | galacto-Dapagliflozin;JVHXJTBJCFBINQ-IFLJBQAJSA-N;D-Galactitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1S)-;Dapagliflozin Galacto Isomer;(1S)-1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-galactitol | | CAS: | 1408245-02-2 | | MF: | C21H25ClO6 | | MW: | 408.87 | | EINECS: | | | Product Categories: | | | Mol File: | 1408245-02-2.mol |  |
| | galacto-Dapagliflozin Chemical Properties |
| storage temp. | Store at -20°C | | solubility | ≤30mg/ml in DMSO;50mg/ml in dimethyl formamide | | form | crystalline solid |
| | galacto-Dapagliflozin Usage And Synthesis |
| Biological Activity | ki = 2 nmgalacto-dapagliflozin is a potent inhibitor of human sglt2.renal glucose transport is mediated by sodium-glucose cotransporters (sglt) 1 and 2. in humans, sglt2 is responsible for the majority of glucose reabsorption in the kidney. | | in vitro | it was found that galacto-dapagliflozin was a selective inhibitor of hsglt2, but was less potent than dapagliflozin for both transporters. both phlorizin and galacto-dapagliflozin rapidly dissociated from sglt2, while dapagliflozin and fluoro-dapagliflozin dissociated from hsglt2 at a rate 10-fold slower. dapagliflozin, fluoro-dapagliflozin, and galacto-dapagliflozin dissociated quickly from hsglt1, and phlorizin readily exchanged with dapagliflozin bound to hsglt1 [1]. | | in vivo | male db/db mice were administered dapagliflozin for 12 weeks. results showed that administration of dapagliflozin could ameliorate hyperglycemia, β-cell damage and albuminuria in db/db mice. serum creatinine, creatinine clearance and blood pressure were not affected by administration of dapagliflozin. dapagliflozin treatment was able to decrease macrophage infiltration in the kidney of db/db mice [2]. | | references | [1] hummel, c. s.,lu, c.,liu, j., et al. structural selectivity of human sglt inhibitors. american journal of physiology.cell physiology 302(2), c373-c382 (2012).
[2] terami n et al. long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. plos one. 2014 jun 24;9(6):e100777.
[3] merovci a et al. dapagliflozin lowers plasma glucose concentration and improves β-cell function. j clin endocrinol metab. 2015 may;100(5):1927-32. |
| | galacto-Dapagliflozin Preparation Products And Raw materials |
|